

Wai C. Wong, et al.  
Serial No.: Not Yet Known  
Filed: Herewith  
Page 2

52 without prejudice to applicants' right to pursue the subject matter of these claims in a future continuation or divisional application.

Please amend claims 20, 28, 41 and 45 as follows:

A<sup>2</sup> --20. (Amended) A pharmaceutical composition comprising a therapeutically effective amount of the compound of claim 13 and a pharmaceutically acceptable carrier.--  
A<sup>5</sup>

A<sup>3</sup> --28. (Amended) A method of treating a subject suffering from benign prostatic hyperplasia which comprises administering to the subject an amount of the compound of claim 13 effective to treat benign prostatic hyperplasia.--

A<sup>4</sup> --41. (Amended) A method of treating a subject suffering from benign prostatic hyperplasia which comprises administering to the subject an amount of the compound of claim 13 in combination with a 5 alpha-reductase inhibitor effective to treat benign prostatic hyperplasia.--

A<sup>5</sup> --45. (Amended) A pharmaceutical composition comprising a therapeutically effective amount of the compound of claim 13 in combination with a therapeutically effective amount of finasteride and a pharmaceutically acceptable carrier.--

Applicants attach hereto as **Exhibit 1** a Marked-up version of the